Le Lézard
Classified in: Environment, Health
Subjects: AWD, RCY, CSR, ENP

DaVita Medical Group Facility Awarded LEED® Gold Status



EL SEGUNDO, Calif., Sept. 13, 2017 /PRNewswire/ -- DaVita Medical Group, a division of DaVita Inc. (NYSE: DVA) and a leading independent medical group in the United States, today announced that its California headquarters facility has been awarded the Leadership in Energy & Environmental Design (LEED®) Gold certification by the U.S. Green Building Council (USGBC).

USGBC scores buildings in seven categories including sustainable sites, water efficiency, energy and atmosphere, materials and resources, indoor environmental quality, innovation in design and regional priority credits. Referred to as the Casa PacifiCA, in El Segundo, California, DaVita Medical Group's building received a Gold certification.

"We believe that being good stewards of our environment and our community are pivotal in our mission to build the leading independent medical group in America," said Jim McPhail, vice president of real estate and center development at DaVita. "By supporting a healthy environment and committing to sustainability we have the opportunity to improve health care in our community."  

Some building highlights of the Casa PacifiCA include:

DaVita, a national leader in sustainability efforts, is dedicated to its organizational initiative to pursue at least LEED® Silver certification for all business offices as part of the organization's 2020 environmental goals. The Casa PacifiCA certification, follows that of DaVita's World Headquarters in Denver, Colorado last year.

Learn more about DaVita's commitment to environmental sustainability for the future here.

About DaVita Medical Group
DaVita Medical Group is a division of DaVita Inc., a Fortune 500® company, that operates and manages medical groups and affiliated physician networks in California, Colorado, Florida, Nevada, New Mexico, Pennsylvania and Washington. A leading independent medical group in America, DaVita Medical Group has over two decades of experience providing coordinated, outcomes-based medical care in a cost-effective manner. DaVita Medical Group's teammates, employed clinicians and affiliated clinicians provided care for approximately 1.7 million patients. For more information, please visit DaVitaMedicalGroup.com.

About DaVita Inc.
DaVita Inc., a Fortune 500® company, is the parent company of DaVita Kidney Care and DaVita Medical Group. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of June 30, 2017, DaVita Kidney Care operated or provided administrative services at 2,445 outpatient dialysis centers located in the United States serving approximately 194,600 patients. The company also operated 217 outpatient dialysis centers located in 11 countries outside the United States. DaVita Medical Group manages and operates medical groups and affiliated physician networks in California, Colorado, Florida, Nevada, New Mexico, Pennsylvania and Washington in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. DaVita Medical Group's teammates, employed clinicians and affiliated clinicians provided care for approximately 1.7 million patients. For more information, please visit DaVita.com/About.

Contact Information

Media:
Jessica Geurkink
(720) 925-3184
Jessica.Geurkink@davita.com         

DaVita Medical Group (PRNewsfoto/DaVita Medical Group)

 

SOURCE DaVita Medical Group


These press releases may also interest you

10 déc 2017
Blessed Herbs Cafe and Mount Zion Rastafarian Church founder and practicing Rasta George Metropoulos today announced the launch of the organization's first holiday season food and cash drive. Directly benefiting the neighborhood's less fortunate...

10 déc 2017
A new article published today in The New England Journal of Medicine shows that 42 percent of diffuse large B cell lymphoma patients treated with axicabtagene ciloleucel, offered commercially under the brand name Yescartatm, remain in remission 15...

10 déc 2017
Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriahtm (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory (r/r)...

10 déc 2017
For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight...

10 déc 2017
Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality...

10 déc 2017
The number of variants identified as being associated with cancer risk and progression is rapidly growing. Meanwhile, advances in medical genomics are paving the way to novel approaches for the diagnosis, management, and treatment of patients with...




News published on 13 september 2017 at 06:35 and distributed by: